QF-Pro®may significantly boost immunotherapy response rates in lung cancer
Our new trial results, published in the Journal of Clinical Oncology show that QF-Pro® identifies 24.5% of non-small cell lung cancer patients, who have low PD-L1 expression scores in fact have significant PD-1/PD-L1 interaction states. These patients are currently missing life saving treatments due to incorrect patient stratification.
PD-1/PD-L1 interaction state predicts patient response to immunotherapy in lung cancer
In a case study accepted by and set to be published in the Journal of Clinical Oncology (JCO), researchers at HAWK Biosystems have validated their QF-Pro® assay for the determination of PD-1/PD-L1 interaction state in non-small cell lung cancer.
Within this study, it was shown that PD-1/PD-L1 interaction state, but not PD-L1 expression, was highly predictive of patient outcome and response to treatment.
PD-L1 expression levels fail to stratify patients for immunotherapy
Within this study, PD-1/PD-L1 interaction states, determined by QF-Pro®, were compared to classical PD-L1 expression scores (determined by IHC). It was shown that PD-L1 expression, the current gold-marker for selecting patient for anti-PD-1/PD-L1 therapies, failed to identify a subset of patient with low PD-L1 score but high PD-1/PD-L1 interaction. These patients make up 25% of NSCLC patients and would benefit from the timely prescription of these treatments.
Unlike PD-L1 score, determination of PD-1/PD-L1 interaction state by QF-Pro® predicts patient outcome and treatment response in NSCLC. Those patients with a higher PD-1/PD-L1 interaction experienced increased survival rates due to the correct therapeutic targeting of this checkpoint.
Read more
When all NSCLC patients are analysed by QF-Pro®, it is seen that 24.5% of patients with a low PD-L1 score have high PD-1/PD-L1 interaction. These patients may miss life saving first-line mono-therapies based on the current gold standard biomarker. Conversely, 22.5% of patients with high PD-L1 scores will not respond due to low interaction status.
Read more
QF-Pro® was used to assess PD-1/PD-L1 interaction states in all patients with a PD-L1 TPS <1%. Here, those patients with an interaction state above our proposed threshold (2% FRET efficiency) responded significantly better to treatment than those patients with no interaction state.
Read moreQF-Pro® is a versatile platform which has to potential to revolutionise clinical trials in the field of immune checkpoint inhibitors. Whilst we have exemplified the power of QF-Pro® by assessing PD-1/PD-L1interaction states, QF-Pro® can be used to quantify the interaction state of any immune checkpoint and is already tested in CTLA-4/CD80 and TIGIT/CD155.
Click here to try QF-Pro®© Copyright HAWK Biosystems . All rights reserved.